ESMO 2016 header

IASLC 2016 Coverage

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.

Tumor, Node, and Metastasis Classification: 8th Edition Changes

Tumor, Node, and Metastasis Classification: 8th Edition Changes

The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.

International Cooperation Vital for Preventing Lung Cancer

International Cooperation Vital for Preventing Lung Cancer

Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.

Radiotherapy Doses Evaluated in NSCLC

Radiotherapy Doses Evaluated in NSCLC

A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.

NSCLC Survival Associated With Institutional Differences in Quality of Care

NSCLC Survival Associated With Institutional Differences in Quality of Care

Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs